Skip to Main content Skip to Navigation
Journal articles

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

Julien Péron 1, 2, 3 Claire Cropet 3 Olivier Tredan 3 Thomas Bachelot 3 Isabelle Ray-Coquard 3 Gilles Clapisson 3 Sylvie Chabaud 3 Irene Philip 3 Christophe Borg 4 Philippe Cassier 3 Inthidar Labidi Galy 3 Catherine Sebban 3 David Perol 3 Pierre Biron 3 Christophe Caux 5 Christine Menetrier-Caux 5 Jean-Yves Blay 3
1 Biostatistiques santé
Département biostatistiques et modélisation pour la santé et l'environnement [LBBE]
2 Université de Lyon
3 Centre Léon Bérard [Lyon]
4 Service d'Oncologie Médicale [CHRU Besançon]
5 Equipe 11
Centre Léon Bérard [Lyon]
Abstract : BACKGROUND: Cancer patients with CD4 lymphopenia have an increased risk of severe toxicity after administration of cytotoxic chemotherapy. The impact of CD4 lymphopenia on long term overall survival (OS) of cancer patients was explored in this work. PATIENTS AND METHODS: The first prospective series (test series) included 219 patients with solid tumours, lymphomas or myelomas receiving chemotherapy within an oncology department in 1999 and 2000. A phenotypic analysis of lymphocyte subsets by flow cytometry was performed before chemotherapy on day 1. The prognostic value of total, CD4, CD8 and CD56 lymphocyte count for OS was tested in a multivariate analysis. The prognostic value of low CD4 counts was then tested in a validation series of 269 patients with metastatic solid tumours in second line treatment included in a prospective observational study in the Centre Leon Berard. RESULTS: In the test series, all patients with metastatic cancers and CD4 lymphopenia ≤ 200/μL (12% of metastatic patients) died within 18 months with a median OS of 5.9 months. CD4 count was an independent prognostic factor for OS and PFS in multivariate analysis. In the validation series, 83 (30%) of patients had CD4 count ≤ 200/μL: their median overall survival was 3.9 months with an 18-month survival rate of 6%. CD4 count was also an independent prognostic factor for overall survival in this series. CONCLUSIONS: CD4 lymphopenia <200/μL is frequent in advanced cancer patients and associated with a very short life expectancy. These patients should be proposed for specific treatment and research approaches.
Document type :
Journal articles
Complete list of metadata
https://www.hal.inserm.fr/inserm-00875714
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Tuesday, October 22, 2013 - 3:35:30 PM
Last modification on : Monday, December 6, 2021 - 10:46:18 AM

Identifiers

Collections

INSERM | CNRS | INRIA | BIOENVIS | UNIV-LYON1 | UDL | POLITIQUES-PUBLIQUES | UNIV-FCOMTE

Citation

Julien Péron, Claire Cropet, Olivier Tredan, Thomas Bachelot, Isabelle Ray-Coquard, et al.. CD4 lymphopenia to identify end-of-life metastatic cancer patients.. European Journal of Cancer, Elsevier, 2013, 49 (5), pp.1080-9. ⟨10.1016/j.ejca.2012.11.003⟩. ⟨inserm-00875714⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

1107